NexImmune, Inc. (NEXI) DCF Valuation

NexImmune, Inc. (NEXI) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

NexImmune, Inc. (NEXI) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Evaluate NexImmune, Inc.'s (NEXI) financial outlook like an expert! This (NEXI) DCF Calculator comes with pre-filled financials and offers you the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -20.4 -27.1 -52.4 -61.6 -28.2 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .4 .6 .9 1.5 1.0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -20.9 -27.7 -53.3 -63.1 -29.2 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 10.1 5.0 81.8 34.6 4.6 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .1 .0
Account Receivables, % 100 100 100 100 100
Inventories .1 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 1.2 2.8 1.0 2.4 1.3 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -1.2 -.9 -2.4 -1.3 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -20.6 -29.4 -54.1 518.9 -29.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -20.3 -28.0 -57.3 520.4 -29.2 -1.3 .0 .0 .0 .0
WACC, % 10.52 10.53 10.53 9.47 10.53 10.31 10.31 10.31 10.31 10.31
PV UFCF
SUM PV UFCF -1.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -3
Equity Value 2
Diluted Shares Outstanding, MM 1
Equity Value Per Share 1.83

What You Will Get

  • Comprehensive NEXI Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Real-Time Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Analysis: Evaluate various scenarios to assess NexImmune’s future prospects.
  • User-Friendly Design: Designed for industry professionals yet easy to navigate for newcomers.

Key Features

  • 🔍 Real-Life NEXI Financials: Pre-filled historical and projected data for NexImmune, Inc. (NEXI).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate NexImmune’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize NexImmune’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review NexImmune’s pre-filled financial data and forecasts.
  3. Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
  5. Step 5: Evaluate the outputs and leverage the results for your investment strategies.

Why Choose This Calculator for NexImmune, Inc. (NEXI)?

  • All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for NexImmune.
  • Flexible Inputs: Modify yellow-highlighted fields to explore different financial scenarios.
  • In-Depth Analysis: Automatically computes NexImmune’s intrinsic value and Net Present Value.
  • Preloaded Information: Historical and projected data provide reliable starting points for analysis.
  • Expert-Level Tool: Perfect for financial analysts, investors, and business consultants focusing on biotech.

Who Should Use This Product?

  • Individual Investors: Gain insights to make informed decisions about purchasing or selling NexImmune, Inc. (NEXI) stock.
  • Financial Analysts: Enhance valuation methodologies with comprehensive financial models tailored for NexImmune, Inc. (NEXI).
  • Consultants: Provide clients with accurate and timely valuation analyses related to NexImmune, Inc. (NEXI).
  • Business Owners: Learn how biopharmaceutical companies like NexImmune, Inc. (NEXI) are valued to inform your own business strategies.
  • Finance Students: Explore valuation principles using case studies and data from NexImmune, Inc. (NEXI).

What the NexImmune Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations specific to NexImmune.
  • Real-World Data: NexImmune’s historical and projected financials preloaded for thorough analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics relevant to NexImmune.
  • Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results tailored to NexImmune's data.

No products were found matching.